EIF1AX: A Potential Drug Target and Biomarker (G1964)

Target Name: EIF1AX

NCBI ID: G1964

EIF1AX

EIF1AX: A Potential Drug Target and Biomarker

EIF1AX (endoplasmic reticulum-associated protein 1Ax) is a protein that is expressed in various cell types, including muscle, nerve, and heart cells. It is a member of the endoplasmic reticulum-associated protein (ERP) family, which includes proteins that play a critical role in the delivery and processing of proteins from the endoplasmic reticulum to the cytoplasm. EIF1AX is unique due to its ability to interact with small molecules, such as drugs, toxins, and diseases, making it an attractive drug target and biomarker.

Disease and Drug Targets

EIF1AX has been identified as a potential drug target for various diseases, including neurodegenerative diseases, cancer, and autoimmune diseases. Its unique ability to interact with small molecules makes it an attractive target for diseases that are characterized by the buildup of abnormal proteins or the disruption of normal cellular processes.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, the buildup of aggregated beta-amyloid peptides and neurofibrillary tangles is thought to contribute to the progression of the disease. EIF1AX has been shown to play a role in the delivery and processing of beta-amyloid peptides from the endoplasmic reticulum to the cytoplasm, which may be a potential target for therapies aimed at reducing the buildup of beta-amyloid peptides.

In cancer, the regulation of endoplasmic reticulum-associated protein (ERP) expression is often disrupted, leading to the production of aberrant proteins that contribute to tumor growth and the development of drug resistance. EIF1AX has been shown to play a role in the regulation of ERP expression in various cancer types, making it a potential target for cancer therapies.

In autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage. The regulation of ERP expression is often disrupted in these diseases, and EIF1AX has been shown to play a role in the regulation of ERP expression in immune cells.

Biomarkers

EIF1AX has also been identified as a potential biomarker for various diseases, including neurodegenerative diseases, cancer, and autoimmune diseases. Its unique ability to interact with small molecules makes it an attractive target for the development of biomarkers that can be used to diagnose or monitor the progression of these diseases.

In neurodegenerative diseases, EIF1AX has been shown to be involved in the regulation of beta-amyloid peptides, which are a hallmark of neurodegeneration. The levels of beta-amyloid peptides in the brain are thought to contribute to the development and progression of these diseases. Therefore, EIF1AX has been shown to be an attractive target for the development of biomarkers that can be used to diagnose or monitor the progression of neurodegenerative diseases.

In cancer, EIF1AX has been shown to play a role in the regulation of ERP expression, which is often disrupted in these diseases. Therefore, EIF1AX has been shown to be an attractive target for the development of biomarkers that can be used to diagnose or monitor the progression of cancer.

In autoimmune diseases, EIF1AX has been shown to play a role in the regulation of ERP expression in immune cells, which are often disrupted in these diseases. Therefore, EIF1AX has been shown to be an attractive target for the development of biomarkers that can be used to diagnose or monitor the progression of autoimmune diseases.

Conclusion

EIF1AX is a unique protein that has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative diseases, cancer, and autoimmune diseases. Its ability

Protein Name: Eukaryotic Translation Initiation Factor 1A X-linked

Functions: Seems to be required for maximal rate of protein biosynthesis. Enhances ribosome dissociation into subunits and stabilizes the binding of the initiator Met-tRNA(I) to 40 S ribosomal subunits

The "EIF1AX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF1AX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets